- PR Newswire•1 hour ago
PARIS, Oct. 28, 2016 /PRNewswire/ -- Sanofi (NYSE: SNY; EURONEXT: SAN) Q3 2016 Change Change (CER) Aggregate Company sales (1) €9,652m +2.1% +3.0% Business net income (2) €2,300m +9.7% +11.1% Business ...
- The Wall Street Journal•2 hours ago
French drugmaker Sanofi lifted its profit outlook for the year after posting better-than-expected third-quarter earnings, and said it planned to complete a $3.82 billion share buyback by the end of 2017....
- American City Business Journals•2 hours ago
A U.S. approval decision for a major drug planned to be marketed by Cambridge-based Sanofi Genzyme that had been expected today may be delayed due to “deficiencies” found during a manufacturing site inspection in France. Sanofi spokesman Jack Cox confirmed in an email that the facility, which conducts the final manufacturing steps for biologic drugs, is known as “Le Trait” and is located in Normandy, France. “Given that the CGMP status of this facility is still under review by the FDA, it is unclear whether this situation will impact the approval for sarilumab,” the company said in the release.
Paris - Paris Delayed Price. Currency in EUR
|Bid||71.12 x 1000|
|Ask||71.74 x 44000|
|Day's Range||71.15 - 73.98|
|52wk Range||25.29 - 73.98|
|1y Target Est||N/A|
|P/E Ratio (ttm)||22.50|
|Avg Vol (3m)||9,472|
|Dividend & Yield||N/A (N/A)|